Transgene: Resumption of Trading on Euronext Paris

Transgene has announced the resumption of trading of its shares on Euronext Paris, effective November 27, 2025. This decision follows the suspension of trading requested on November 26, 2025, in anticipation of the results of its capital increase. The company's stock, identified by the ISIN FR0005175080, will be traded again at the market opening.

The press release states that the capital increase was a key element, although the details of this transaction are not specified in the document. Transgene, a biotechnology company, is continuing to develop its portfolio of cancer immunotherapies, a field where competition is fierce and the market is constantly evolving.